Australian shares closed the week higher, tracking Asian markets, despite Wall Street's concerns about high interest rates.
The S&P/ASX 200 Index rose 0.6% or 49.3 points to close at 8,250.5.
Anticipated fewer rate cuts from the US Federal Reserves, coupled with potential inflationary policies from President-elect Trump hit shares while sending bond yields higher and making the dollar stronger, Reuters reported.
In company news, the Australian Securities Exchange (ASX:ASX) is looking to clamp down on listed companies allegedly providing misleading or evasive information in their market disclosures, according to a report by The Australian.
Imugene (ASX:IMU) dosed the first Australian patient for its phase 1b clinical trial of its CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital in Sydney.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。